Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Cardiotoxicity and Other Adverse Events Associated With Mitoxantrone Treatment for MS
Neurol 74:1822-1826, Kingwell,E., et al, 2010
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis
Neruol 90:852-854, Ferraro, D.,et al, 2018
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
NEJM 362:402-415, 456, Cohen,J.A.,et al, 2010
Longitudinal Study of Vision and Retinal Nerve Fiber Layer Thickness in Multiple Sclerosis
Ann Neurol 67:749-760, Talman,L.S., et al, 2010
Evidence for Acute Neurotoxicity After Chemotherapy
Ann Neurol 68:806-815, Petzold,A.,et al, 2010
What Do We Really See When We Look at Magnetic Resonance Images?
Ann Neurol 62:207-208, Filippi,M. &Hartung,H.-P., 2007
Interferon Beta-1a for Brain Tissue Loss in Patients at Presentation with Syndromes Suggestive of Multiple Sclerosis: A Randomised, Double-Blind, Placebo-Controlled Trial
Lancet 364:1489-1496,1463, Filippi,M.,et al, 2004
Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis
Brain 126:433-437, Filippi,M.,et al, 2003
A Wallerian Degeneration Pattern in Patients at Risk for MS
Neurol 54:1155-1160, Simion,J.H.,et al, 2003
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Lesions of the Corpus Callosum: MR Imaging and Differential Considerations in Adults and Children
AJR 179:251-257, Bourekas,E.C.,et al, 2002
Cardiac Adverse Effects Associated with Mitoxantrone (Novantrone) Therapy in Patients with MS
Neurol 59:909-913, Ghalie,R.G.,et al, 2002
Multiple Sclerosis and Magnetic Resonance Imaging
Arch Neurol 58:35-36, Racke,M.K.,et al, 2001
Clinical Presentation of Left Atrial Cardiac Myxoma
Medicine 80:159-172, Pinede,L.,et al, 2001
A Longitudinal MRI Study of Histopathologically Defined Hypointense Multiple Sclerosis Lesions
Ann Neurol 49:793-796, Bitsch,A.,et al, 2001
Autologous Hematopoietic Stem Cell Transplantation Suppresses Gd-enhanced MRI activity in MS
Neurol 57:62-68, Mancardi,G.L.,et al, 2001
Narcolepsy Associated with Other Central Nervous System Disorders
Neurol 57:539-541, Malik,S.,et al, 2001
14-3-3 Protein in the CSF as Prognostic Marker in Early Multiple Sclerosis
Neurol 57:722-724, Martinez-Yelamos,A.,et al, 2001
The Differential Diagnosis of Multiple Sclerosis
JNNP 71(suppl II):ii9-ii15, Scolding, N., 2001
Retinocochleocerebral Vasculopathy
Medicine 77:12-40, Petty,G.W.,et al, 1998
Axonal Transection in the Lesions of Multiple Sclerosis
NEJM 338:278-285, 3231998., Trapp,B.D.,et al, 1998
Hypothermia in Multiple Sclerosis
JNNP 61:369-375, White,K.D.,et al, 1996
Linomide Reduces the Rate of Active Lesions in Relapsing-Remitting Multiple Sclerosis
Neurol 47:895-900, Anderson,O.,et al, 1996
Multiple Sclerosis as a Cause of Atrial Fibrillation and Electrocardiographic Changes
Arch Neurol 49:422-424, Schroth,W.S.,et al, 1992
Peripheral Nervous System Involvement in Multiple Sclerosis
Neurol 41:457-460, Zee,P.C.,et al, 1991
Lyme Neuroborreliosis:Central Nervous System Manifestations
Neurol 39:753-759, Halperin,J.J.,et al, 1989
Evidence for Central Nervous System Demyelination in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Neurol 37:1291-1294, Mendell,J.R.,et al, 1987
Peripheral Nerve Abnormality in Multiple Sclerosis
Ann Neurol 2:41, Pollock,M.,et al, 1977